ArticleComputational and structural biotechnology journal2021

Structural binding site comparisons reveal Crizotinib as a novel LRRK2 inhibitor.

Sarah Naomi Bolz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.